DRF-1042

DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype .


Cat. No.: EX-A15157	Purity: >98%

	Chemical structure of DRF-1042

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	485	In-stock
250mg	785	In-stock
500mg	1285	In-stock
1g	1985	In-stock
5g	get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	200619-13-2
Purity	>98%
Formula	C22H20N2O6
Mol Weight	408.404

Reference:	[1]. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. [2]. Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.
CoA	CoA of DRF-1042

Smiles:	O=C1[C@](CC)(C2=C(C(N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)=O)CO1)O


		Search